Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial.

CONCLUSIONS: Thrombomodulin alfa did not improve the 90-day survival proportion. The present results suggest that the use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis not be recommended. Clinical trial registration available at www.clinicaltrials.gov, ID: NCT02739165. PMID: 31917621 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31917621?dopt=Abstract

Source: American Journal of Respiratory and Critical Care Medicine - January 8, 2020 Category: Respiratory Medicine Authors: Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, Johkoh T, Fujimoto K, Ichikado K, Matsuzawa Y, Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, To Tags: Am J Respir Crit Care Med Source Type: research